Resumo

VERDUGUEZ-ORELLANA, Aleida; GUZMAN-RIVERO, Miguel; ROJAS, Ernesto  e  CHOQUE MARTINEZ, Esther. Hepatic and renal evaluation in patients that received jointly zinc and antituberculosis shortened treatment . Gac Med Bol [online]. 2019, vol.42, n.1, pp.06-10. ISSN 1012-2966.

Tuberculosis therapy with the 2RHZE/4HE scheme comprises the administration for six months of rifampin, isoniazid, pyrazinamide and ethambutol, of which the first three are potentially hepatotoxic and exceptionally nephrotoxic. Tuberculosis produces depletion of the zinc concentration which increases the susceptibility to chronicity of the infection. Objective: to evaluate the effect of co-administration of zinc and 2RHZE/4HE therapy on hepatic and renal function in patients with pulmonary tuberculosis. Methods: a, descriptive case-control, randomized double-blind study. 22 patients with pulmonary tuberculosis receiving pharmacological therapy and 22 healthy controls recruited in the health centers Sebastián Pagador and Alalay. The patients were randomly divided into two groups. Who were given zinc (45mg/day) or placebo for three months. All patients were blood sampling before and after intervention to measure hepatic and renal functional tests. For the control subjects were blood sampling before the study to do the same test. Results: no deference was found in the concentration of specific markers of hepatic or renal damage. Conclusions: the addition of a daily supplement of 45 mg of zinc to 2RHZE/4HE therapy did not cause hepatic, neither renal damage in the people evaluated.

Palavras-chave : hepatic and renal function; pulmonary tuberculosis; zinc; nutritional supplement.

        · resumo em Espanhol     · texto em Espanhol     · Espanhol ( pdf )